Holen Sie sich die Stockscreener-App
27.61
0.58%
-0.1796
Schlusskurs vom Vortag:
$27.79
Offen:
$27.79
24-Stunden-Volumen:
89,983
Relative Volume:
0.11
Marktkapitalisierung:
$1.60B
Einnahmen:
$868.45M
Nettoeinkommen (Verlust:
$158.69M
KGV:
10.19
EPS:
2.7087
Netto-Cashflow:
$328.64M
1W Leistung:
-2.47%
1M Leistung:
-23.27%
6M Leistung:
-14.70%
1J Leistung:
-15.56%
1-Tages-Spanne:
$27.56
$27.93
1-Wochen-Bereich:
$27.39
$29.00
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
27.61 | 1.61B | 868.45M | 158.69M | 328.64M | 2.7087 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.31 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.75 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.41 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.06 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.40 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Herabstufung | Truist | Buy → Hold |
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Harmony Biosciences Reports 2025 Revenue Growth, Issues 2026 Outlook - MyChesCo
Harmony Biosciences Holdings, Inc. $HRMY Shares Acquired by American Century Companies Inc. - MarketBeat
Does Mixed Q4 Results and Reaffirmed WAKIX Guidance Change The Bull Case For Harmony Biosciences (HRMY)? - simplywall.st
Harmony Biosciences Eyes Blockbuster Future After Record Year - TipRanks
HRMY Technical Analysis & Stock Price Forecast - Intellectia AI
Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
Harmony Biosciences Holdings, Inc. (HRMY): Investor Outlook on Its Promising 45% Upside Potential - DirectorsTalk Interviews
HRMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
HC Wainwright Issues Pessimistic Forecast for HRMY Earnings - MarketBeat
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31 - Bitget
Harmony Biosciences (NASDAQ:HRMY) Downgraded by Wall Street Zen to Hold - MarketBeat
A Look At Harmony Biosciences (HRMY) Valuation After Guidance Reaffirmation And New Pediatric WAKIX Approval - Sahm
MSN - MSN
Harmony Biosciences Downgrades Put Wakix Patent Risks In Sharp Focus - Yahoo Finance
HC Wainwright Issues Negative Estimate for HRMY Earnings - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Stock Rating Lowered by Zacks Research - MarketBeat
US applications for jobless aid rose modestly to 212,000 last week as layoffs remain at historically healthy levels - Bitget
Safe Bulkers, Inc. to Participate in the Dry Bulk Shipping Panel at the DNB Carnegie Energy & Shipping Conference in Oslo - Bitget
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Yahoo Finance
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval - simplywall.st
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
20 Best Investments in 2026 - Insider Monkey
UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00 - MarketBeat
Harmony Biosciences (HRMY): UBS Lowers Price Target to $36 | HRM - GuruFocus
HC Wainwright Reiterates Buy Rating for HRMY with $55 Target | H - GuruFocus
Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry - Investing.com
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility - Markets Mojo
Bank of America Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $28.00 - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Deutsche Bank Adjusts Harmony Biosciences PT to $30 From $31, Maintains Hold Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS - StreetInsider
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
B of A Securities Lowers Harmony Biosciences (HRMY) Price Target to $28 | HRMY Stock News - GuruFocus
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target - Investing.com Australia
Harmony Biosciences price target lowered to $28 from $32 at BofA - TipRanks
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SW - GuruFocus
Harmony Biosciences (HRMY) Margin Compression In FY 2025 Tests Bullish Profitability Narrative - simplywall.st
Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Hi - GuruFocus
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for 2026 - marketscreener.com
Harmony Biosciences (HRMY) Reports Strong Q4 2025 Results, Eyes Blockbuster Revenue - GuruFocus
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $28 at BofA Securities - StreetInsider
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target By Investing.com - Investing.com Canada
Truist SecuritiesReinstates $25 target on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):